(VIANEWS) – Assured Guaranty Ltd. (AGO), Halozyme Therapeutics (HALO), ANI Pharmaceuticals (ANIP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Assured Guaranty Ltd. (AGO)
142.7% sales growth and 13.25% return on equity
Assured Guaranty Ltd., through its subsidiaries, provides credit protection products to public finance, infrastructure, and structured finance markets in the United States and internationally. The company operates in two segments, Insurance and Asset Management. It offers financial guaranty insurance that protects holders of debt instruments and other monetary obligations from defaults in scheduled payments. The company insures and reinsures various debt obligations, including bonds issued by the United States state, governmental authorities, or municipal governmental authorities; and notes issued to finance infrastructure projects. It also insures and reinsures various types of the U.S. public finance obligations, such as general obligation, tax-backed, municipal utility, transportation, healthcare, higher education, infrastructure, housing revenue, investor-owned utility, renewable energy, and other public finance bonds; non-U.S. public finance obligations comprising regulated utilities, infrastructure finance, sovereign and sub-sovereign, renewable energy bonds, pooled infrastructure, and other public finance obligations; and the U.S. and non-U.S. Structured finance obligations, including residential mortgage-backed securities, insurance securitization obligations, consumer receivables securities, pooled corporate obligations, financial products, and other structured finance securities. In addition, the company provides asset management services comprising investment advisory services, including management of collateralized loan obligations and opportunity funds to outside investors. It markets its financial guaranty insurance directly to issuers and underwriters of public finance and structured finance securities, as well as to investors in such obligations. Assured Guaranty Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Assured Guaranty Ltd. has a trailing twelve months EPS of $12.21.
PE Ratio
Assured Guaranty Ltd. has a trailing twelve months price to earnings ratio of 6.97. Meaning, the purchaser of the share is investing $6.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.25%.
Moving Average
Assured Guaranty Ltd.’s worth is higher than its 50-day moving average of $78.99 and above its 200-day moving average of $80.45.
Yearly Top and Bottom Value
Assured Guaranty Ltd.’s stock is valued at $85.12 at 06:22 EST, way under its 52-week high of $96.60 and way above its 52-week low of $59.01.
2. Halozyme Therapeutics (HALO)
33.4% sales growth and 153.16% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.58.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 22.94. Meaning, the purchaser of the share is investing $22.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 153.16%.
Sales Growth
Halozyme Therapeutics’s sales growth is 17.8% for the current quarter and 33.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.7%, now sitting on 873.3M for the twelve trailing months.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $59.18 at 06:22 EST, under its 52-week high of $65.53 and way higher than its 52-week low of $32.83.
3. ANI Pharmaceuticals (ANIP)
25.8% sales growth and 5.9% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $1.19.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 48.6. Meaning, the purchaser of the share is investing $48.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.9%.
Previous days news about ANI Pharmaceuticals(ANIP)
- According to Zacks on Friday, 18 October, "Some other top-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals (CPRX Quick QuoteCPRX – Free Report) , ANI Pharmaceuticals (ANIP Quick QuoteANIP – Free Report) and Alnylam Pharmaceuticals (ALNY Quick QuoteALNY – Free Report) . "
4. Meta Platforms (META)
15.4% sales growth and 35.37% return on equity
Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California
Earnings Per Share
As for profitability, Meta Platforms has a trailing twelve months EPS of $14.86.
PE Ratio
Meta Platforms has a trailing twelve months price to earnings ratio of 34.45. Meaning, the purchaser of the share is investing $34.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.37%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 16, 2024, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 0.35%.
Moving Average
Meta Platforms’s worth is below its 50-day moving average of $546.46 and above its 200-day moving average of $491.26.
Yearly Top and Bottom Value
Meta Platforms’s stock is valued at $511.90 at 06:22 EST, way below its 52-week high of $602.95 and way above its 52-week low of $279.40.
Previous days news about Meta Platforms(META)
- According to FXStreet on Thursday, 17 October, "Cisco has additionally become a primary vendor for Meta Platforms (META), which is using Cisco hardware such as networking switches to build out its newest AI network fabric: Disaggregated Scheduled Fabric. "
- According to Zacks on Thursday, 17 October, "These include FTAI Aviation (FTAI Quick QuoteFTAI – Free Report) , Vistra Energy (VST Quick QuoteVST – Free Report) , Nvidia (NVDA Quick QuoteNVDA – Free Report) , Vertiv Holdings (VRT Quick QuoteVRT – Free Report) , and Facebook-parent Meta Platforms (META Quick QuoteMETA – Free Report) ."
5. Group 1 Automotive (GPI)
14.8% sales growth and 20.73% return on equity
Group 1 Automotive, Inc., through its subsidiaries, operates in the automotive retail industry. The company sells new and used cars, light trucks, and vehicle parts, as well as service and insurance contracts; arranges related vehicle financing; and offers automotive maintenance and repair services. It operates primarily in 17 states in the United States; and 35 towns in the United Kingdom. As of July 11, 2022, the company owned and operated 204 automotive dealerships, 273 franchises, and 47 collision centers that offer 35 brands of automobiles. Group 1 Automotive, Inc. was incorporated in 1995 and is based in Houston, Texas.
Earnings Per Share
As for profitability, Group 1 Automotive has a trailing twelve months EPS of $40.52.
PE Ratio
Group 1 Automotive has a trailing twelve months price to earnings ratio of 8.93. Meaning, the purchaser of the share is investing $8.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.73%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3%, now sitting on 18.35B for the twelve trailing months.
6. QCR Holdings (QCRH)
12.7% sales growth and 12.94% return on equity
QCR Holdings, Inc., a multi-bank holding company, provides commercial and consumer banking, and trust and asset management services. Its deposit products include noninterest-bearing demand, interest-bearing demand, time, and brokered deposits. The company also provides various commercial and retail lending/leasing, and investment services to corporations, partnerships, individuals, and government agencies. Its loan portfolio comprises loans to small and mid-sized businesses; business loans, including lines of credit for working capital and operational purposes; term loans for the acquisition of facilities, equipment, and other purposes; commercial and residential real estate loans; and installment and other consumer loans, such as home improvement, home equity, motor vehicle, and signature loans, as well as small personal credit lines. In addition, the company engages in leasing of machinery and equipment to commercial and industrial businesses under direct financing lease contracts; and issuance of trust preferred securities. It serves the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny, and Springfield communities. The company was founded in 1993 and is headquartered in Moline, Illinois.
Earnings Per Share
As for profitability, QCR Holdings has a trailing twelve months EPS of $6.74.
PE Ratio
QCR Holdings has a trailing twelve months price to earnings ratio of 11.03. Meaning, the purchaser of the share is investing $11.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.94%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 13, 2024, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 0.32%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 0.7% and a drop 20.3% for the next.
7. Universal Stainless & Alloy Products (USAP)
6.3% sales growth and 7.6% return on equity
Universal Stainless & Alloy Products, Inc., together with its subsidiaries, manufactures and markets semi-finished and finished specialty steel products in the United States and internationally. Its products include stainless steel, nickel alloys, tool steel, and various other alloyed steels. The company offers semi-finished and finished long products in the form of ingots, blooms, billets, and bars; flat rolled products, such as slabs and plates; and customized shapes primarily for original equipment manufacturers (OEMs), which are cold rolled from purchased coiled strip, flat bar, or extruded bar. Its semi-finished long products are primarily used to produce rods; and finished bar products that are principally used by OEMs and by service center customers for distribution to various end users. The company also offers conversion services on materials supplied by its customers. Its products are used in aerospace, power generation, oil and gas, heavy equipment, general, and automotive industries, as well as in the manufacturing of equipment for food handling, health and medical, chemical processing, and pollution control; and manufacturing of metals, plastics, paper and aluminum extrusions, pharmaceuticals, electronics, and optics. The company sells its products to service centers, forgers, rerollers, and OEMs. Universal Stainless & Alloy Products, Inc. was founded in 1994 and is headquartered in Bridgeville, Pennsylvania.
Earnings Per Share
As for profitability, Universal Stainless & Alloy Products has a trailing twelve months EPS of $1.82.
PE Ratio
Universal Stainless & Alloy Products has a trailing twelve months price to earnings ratio of 21.79. Meaning, the purchaser of the share is investing $21.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.6%.
Volume
Today’s last reported volume for Universal Stainless & Alloy Products is 74217 which is 43.29% below its average volume of 130873.
